<DOC>
	<DOC>NCT00517296</DOC>
	<brief_summary>This study is to assess whether utilizing endoscopic ultrasound(EUS) to guide treatment can improve durable fistula healing in patients with Crohn's perianal fistulas and to get preliminary information regarding the effectiveness of Adalimumab for Crohn's perianal fistulas.</brief_summary>
	<brief_title>Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Fistula</mesh_term>
	<mesh_term>Rectal Fistula</mesh_term>
	<criteria>A patient may be considered for study participation if all of the following apply: Male and Female aged 18 years or older; and A confirmed diagnosis of Crohn's disease and one or more identifiable perianal fistulas. A patient will be excluded from the study if one or more of the following apply: Females who are pregnant or breast feeding; Infliximab received within 6 weeks prior to study entry; Patients who cannot take, or refuse to take concomitant immunosuppressive therapy with either azathioprine, 6mercaptopurine, or methotrexate; Unless patient has been intolerant of these therapies in the past or is contraindicated as determined by the investigator; Patients who cannot take, or refuse to take concomitant antibiotic therapy; Patients with severe anal stenosis or tenderness which would preclude colonoscopy and / or rectal EUS; Patients who cannot take or refuse to take adalimumab; Patients with active or latent tuberculosis; Patients who have had systemic antibiotic, antiviral or antifungal treatment(s) within 3 weeks prior to Screening for all nonCrohn's related infections; Patients concurrently taking anakinra (Kineret); Patients with a history of cancer or lymphoproliferative disease other than a successfully and completely treated cutaneous squamous cell or basal cell carcinoma or carcinoma insitu of the cervix; Patients with chronic hematologic problems such as bleeding dyscrasias; Patients with a history of demyelinating disease (i.e. multiple sclerosis); and Patients with congestive heart failure.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>